Sarepta (SRPT) Q4 2025: $193M Inventory Charge Resets Margin Structure as Gene Therapy Messaging Overhaul Begins

2026-02-26 | By EarningsIQ Research

Sarepta enters 2026 recalibrating both its cost structure and commercial strategy, as a $193 million inventory charge and a critical re-education push for Elevitus signal a transition year for the business. The company’s guidance and commentary emphasize that the full impact of new initiatives will be delayed, with near-term headwinds but longer-term conviction in gene therapy adoption and pipeline milestones. Investors should focus on execution against educational campaigns and the evolving siRNA pipeline as the key drivers of future value.

Summary

• Margin Structure Reset: Inventory and production write-downs reshape gross margin expectations for 2026.
• Gene Therapy Demand Rebuild: Elevitus uptake hinges on new educational outreach and physician re-engagement.
• Pipeline Milestones Loom: siRNA clinical readouts and regulatory meetings are set to define the next phase of growth.

Business Overview

Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, primarily Duchenne muscular dystrophy (DMD). The company’s revenue is driven by two major segments: PMO therapies, a suite of exon-skipping drugs for DMD, and Elevitus, a one-time gene therapy for ambulatory DMD patients. Sarepta also partners with Roche for ex-US commercialization and is advancing a pipeline of siRNA (small interfering RNA) therapies for neuromuscular, pulmonary, and CNS diseases.

Performance Analysis

Sarepta reported total 2025 revenues of $2.2 billion, up 16% year over year, with $1.86 billion from product sales and $334 million from collaborations, contract manufacturing, and royalties. The PMO franchise delivered $966 million, remaining stable despite some cannibalization from Elevitus. Elevitus contributed $899 million for the year, but Q4 revenue of $110 million was impacted by a severe flu season and rescheduled infusions.

Gross margin was pressured by a $193 million charge for excess inventory and purchase commitment cancellations, as Sarepta recalibrated manufacturing plans to match the narrower initial Elevitus label. Nearly half of 2025’s $840 million cost of sales stemmed from failed batches and inventory write-downs. Excluding these, core product margins were in the low 80% range; for 2026, management expects margins in the high 70% range as production volumes normalize. The company ended 2025 with $954 million in cash and investments, and positive operating cash flow, having proactively refinanced its 2027 convertible debt.

• Elevitus Uptake Lags: Gene therapy adoption slowed after safety events in 2025, requiring a reset in messaging and outreach to address physician and patient hesitancy.
• PMO Franchise Stability: Chronic exon-skipping therapies remain resilient, with high compliance and only modest declines as patients transition to gene therapy.
• Collaboration Revenue Boost: 2026 will see a $40 million milestone from Roche’s Japan launch and $325 million in non-cash revenue as Roche declined a specific program option.

While near-term Elevitus sales are expected to be flat to down 15% in Q1, Sarepta’s guidance for 2026 product revenue ($1.2–1.4 billion) is weighted toward a late-year acceleration, contingent on the impact of new commercial initiatives.

Executive Commentary

Strategic Positioning

1. Commercial Reset for Elevitus

After unexpected safety events and subsequent FDA label changes in 2025, Sarepta is rebuilding trust and understanding around Elevitus, the only FDA-approved gene therapy for DMD. The company is rolling out new educational materials, expanding its field force, and targeting both treatment centers and community physicians to address an “information deficit” that has led to patient and physician hesitancy. Management expects these efforts to drive new demand, but with a lag of several quarters due to long lead times from education to infusion.

2. PMO Franchise Defends Its Base

The exon-skipping PMO therapies (Exondys 51, Vyondys 53, Amondys 45) have demonstrated surprising durability, maintaining high compliance rates and stable revenues despite some cannibalization from gene therapy. Sarepta is pursuing traditional FDA approval for Avondys and Byondys, leveraging a decade of real-world evidence and high patient loyalty. The company is also monitoring potential competitive threats from emerging exon-skipping entrants, but sees its data and patient advocacy as a strong moat.

3. siRNA Pipeline Advances Toward Value Inflection

Sarepta’s partnership with Arrowhead has seeded a portfolio of five clinical-stage siRNA programs, targeting neuromuscular (DM1, FSHD), pulmonary (IPF), and CNS (SCA2, Huntington’s) diseases. The company is emphasizing the potential for best-in-class muscle penetration and safety, with key proof-of-concept data for DM1 and FSHD expected in the current quarter. Early readouts will focus on safety and muscle concentration, with the goal of rapid progression to pivotal studies and potential accelerated approval pathways.

4. Manufacturing and Cost Structure Realignment

2025’s inventory write-down and production recalibration were necessary to align supply with a narrower initial Elevitus label, but management expects improved gross margins and fewer period charges in 2026. The company is targeting $800–900 million in non-GAAP operating expense for the year, down from $1.85 billion in 2025 (which included significant Arrowhead collaboration payments).

5. Leadership Transition and Cultural Continuity

CEO Doug Ingram announced plans to retire by the end of 2026, with the board considering both internal and external candidates. Continuity of culture and execution focus are emphasized as critical, given the company’s patient-centric mission and the execution demands of its pipeline and commercial reset.

Key Considerations

Sarepta’s 2026 outlook is defined by a dual reset: a commercial rebuild for Elevitus and a cost structure recalibration. The company’s ability to convert educational efforts into new gene therapy starts, while sustaining PMO loyalty and executing on siRNA milestones, will determine its long-term trajectory.

Key Considerations:

• Educational Campaign Execution: The speed and effectiveness of physician and patient re-engagement will drive Elevitus demand recovery.
• PMO Resilience Amid Cannibalization: Chronic therapy compliance and real-world data support a stable revenue base, but competition and gene therapy adoption are ongoing threats.
• Pipeline Data as a Catalyst: siRNA proof-of-concept and regulatory interactions are near-term value inflection points.
• Margin Recovery Dependent on Volume: Gross margin improvement relies on stable production and avoidance of further write-downs.
• Leadership Transition Risk: CEO succession introduces uncertainty but also offers an opportunity for refreshed execution focus.

Risks

Near-term Elevitus sales are highly sensitive to the pace of education-driven demand recovery, and the long patient lead times create quarter-to-quarter variability. Manufacturing and inventory risks remain if demand does not rebound as anticipated. Pipeline execution risk is elevated as siRNA programs enter pivotal planning without established clinical benchmarks. CEO transition and potential emerging competitors in exon-skipping therapies add further uncertainty.

Forward Outlook

For Q1 2026, Sarepta guided to:

• Net product revenue flat to down 15% sequentially, reflecting Elevitus demand lag

For full-year 2026, management provided:

• Net product revenue guidance of $1.2–1.4 billion (PMO stable, Elevitus recovery weighted to the second half)
• Collaboration, contract manufacturing, and royalty revenue guidance of $450–550 million
• Non-GAAP operating expense target of $800–900 million

Management highlighted several factors that will shape 2026:

• Educational initiatives for Elevitus will take several quarters to influence demand
• Key siRNA data readouts and regulatory meetings are expected in H1 and H2

Takeaways

Sarepta’s investment thesis hinges on the successful reacceleration of Elevitus and pipeline execution, with cost discipline and PMO stability providing ballast.

• Gene Therapy Recovery: Elevitus demand is a function of educational outreach and time-to-infusion, with near-term softness but longer-term potential if messaging lands.
• Pipeline Optionality: siRNA programs in DM1, FSHD, and CNS represent high-value catalysts, but clinical and regulatory risk is non-trivial.
• Margin and Cash Flow Watch: Inventory and production charges have reset the margin base, but cash flow remains positive and balance sheet risk is manageable.

Conclusion

Sarepta’s 2026 is a year of transition, with commercial, operational, and leadership changes underway. The company’s ability to convert educational initiatives into Elevitus growth and deliver on siRNA milestones will be the critical levers for valuation and strategic positioning over the next 12–18 months.

Industry Read-Through

Sarepta’s experience highlights the volatility of one-time gene therapy launches in rare diseases, where initial safety events can dramatically reshape adoption curves and force a reset in commercial strategy. The necessity of robust real-world evidence and educational outreach is a lesson for all gene therapy developers. Manufacturing flexibility and inventory management are critical as demand projections shift with regulatory or market dynamics. The growing focus on siRNA and next-generation modalities signals an industry-wide pivot toward differentiated delivery and muscle penetration, with clinical benchmarks and regulatory clarity still evolving. Companies across rare disease, gene therapy, and neuromuscular spaces should closely monitor Sarepta’s execution on education, pipeline progression, and cost discipline as bellwethers for sector risk and opportunity.

SRPT Healthcare Biotechnology Gene Therapy siRNA Rare Disease Duchenne Pipeline